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Background: Suicide is a major public health problem. About 90% of suicide victims
have one or more major psychiatric disorder, with a reported 20-fold increased risk for
suicide in patients with affective disorders in comparison with healthy subjects. Repetitive
transcranial magnetic stimulation (rTMS) has been established as an effective alternative or
adjunctive treatment option for patients with depressive disorders, but little is known
about its effects on suicide risk.
Objective: For the assessment of the effectiveness of rTMS on suicidal ideation and
behaviors, we performed a retrospective analysis of a large sample of patients with
depressive disorders, who were treated with rTMS.
Methods: We analyzed the records of 711 TMS in- and out-patients with depressive
affective disorders in a tertiary referral hospital between 2002 and 2017. Out of these
patients we were able to collect Hamilton depression rating scale (HAMD) data of 332
patients (180 females, 152 males; age range 20 to 79 years; mean age 47.3 ± 12.3) for
which we analyzed the change of suicidal ideation by using item 3 (suicidality) of HAMD.
Results: Out of all 711 patients treated with rTMS for their depression, one patient (0.1%)
committed suicide during the TMS treatment. In the statistical analysis of the subsample
with 332 patients there was an overall amelioration of depressive symptoms accompanied
by a signiﬁcant decrease in the suicidality item with a medium effect size. Decrease in
suicidality was not inferior to changes in other items as indicated by effect sizes. Forty-
seven percent of patients showed an amelioration in suicidality, 41.3% of patients did not
show a change in their suicidality’s scores, and 11.7% of patients showed an increase in
suicidality’s scores from baseline to ﬁnal rating. Correlation of item 3 (suicidality) and item 7
(drive) demonstrated a signiﬁcant positive association, revealing improved drive with a
parallel decreased suicidality.
Conclusion: Based on the proposed data, there is no evidence that rTMS increases the
risk for suicide during the course of the treatment. Conversely, rTMS tends to reduceg January 2020 | Volume 10 | Article 9291
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Frontiers in Psychiatry | www.frontiersin.orsuicidal ideation. Our ﬁndings call for further rTMS controlled studies using large sample
sizes and speciﬁc suicidality assessment measures to obtain more conclusive results.Keywords: transcranial magnetic stimulation, suicide, suicidal ideation, depression, brain stimulation, rTMSINTRODUCTION
Suicide is a major public health problem. World-wide nearly 1
million lives are lost each year because of suicide and 3–5%
adults committed at least one suicide attempt at some point in
their life (1–3). Although those numbers of people dying of
suicide are already high, according to the World Health
Organization they are presumably underestimated, and that for
each adult who dies by suicide, there may have been more than
20 others attempting suicide (4). Suicidal behavior is a very
complex, multi-factorial behavior, involving several medical-
biologic, psychosocial, and cultural components (5). The
coexistence of mental disorders in suicidal subjects has been
widely studied. Psychological autopsy studies from different
parts of the world found high prevalence of mental disorders
in suicide victims, indicating that around 90% of them have one
or more axis I (mostly untreated) major psychiatric disorders at
the time of their death (6–8). Among those disorders, mood
disorders represent the major risk factor for suicidal ideation and
suicide attempts (9, 10, 11). In comparison with healthy subjects,
a 20-fold increased risk was reported for the patients with
affective disorders (12).
Moreover, affective disorders do not only increase the risk of
suicidal ideation and tendency to attempt suicide but also the risk
of a suicidal death. It is estimated that between 50 and 70% of all
suicide victims are related to depressive and other mood
disorders (ICD-10 F3); (13–15), with increased lethality of
suicide attempts in patients with major affective disorders
being reported (16).
The general recommendation to reduce suicide risk is the
effective treatment of the underlying depressive disorder, with
medications and psychosocial interventions including
psychotherapy being the main therapy modalities (17).
However, there exist several difﬁculties. First, neither
antidepressants nor psychotherapy work fast enough for
reduction of suicidal ideation. Second, even for medications
with well-established reduction in suicidal behavior such as
lithium, effectiveness is limited (18). Third, the prescription of
antidepressants may offer the depressed patient a potential
suicide method, e.g. , by intoxication with tricyclic
antidepressants, which are known for their cardiotoxicity (19).
Fourth, the reporting of an association between increased
suicidal ideation and antidepressant treatment in controlled
clinical trials of antidepressants has added more difﬁculty to
the connection between depression, its pharmacological
treatment, and suicidality (20–23). The mechanism through
which antidepressant medication might increase suicidality is
yet not understood. A possible explanation for conﬂicting results
concerning the relationship of antidepressant treatment and
suicide risk is a transient increase of suicidal behavior afterg 2initiation of treatment. In detail, it has been suggested that
antidepressants may energize depressed patients before they
lead to mood improvement (24). This period of increased
impulsivity with ongoing desperation may be related to
increased suicidal behavior. Also, side-effects of antidepressants
such as worsening of irritability, agitation, and insomnia could
ease suicidal ideation and behavior (25, 26). Other results
suggested that suicidal behavior in patients taking
antidepressants is mostly the consequence of the lack of
antidepressant effect and is rarely the result of suicide-inducing
potential of antidepressants (27). All of the above-mentioned
concerns indicate the need for more safer and more effective
interventions to reduce suicide risk.
Beside pharmacotherapy and psychotherapy brain
stimulation methods have gained increasing relevance in the
treatment of depression during the last decades (28). Electric
convulsive therapy (ECT) is an established antidepressant
method with clearly proven efﬁcacy for fast improvement of
suicidal behavior, however, the use of ECT is limited by safety
concerns and adverse effects (29).
Repetitive transcranial magnetic stimulation (rTMS) is a non-
invasive brain stimulation technique, that has emerged in the last
30 years and is applied in various neuropsychiatric conditions
(30). rTMS uses pulsed magnetic ﬁelds with an intensity of up to
3T to induce neuronal depolarization in superﬁcial cortical areas.
For the treatment of depressions several stimulation protocols
have been developed with high frequency rTMS of the left
dorsolateral prefrontal cortex being the most established
protocol (30).
In 2008, rTMS was approved for use by the FDA as a
treatment for major depression for patients who do not
respond to at least one antidepressant medication in the
current episode (31) (FDA approval K061053).
The efﬁcacy of rTMS is supported by multiple double blind,
randomized controlled trials (32–34) that are summarized in
several systematic meta-analysis, reviews, and evidence-based
guidelines (30, 35). In general, the focus was more set on the
efﬁcacy of rTMS in patients with TRD (treatment resistant
depression), considering its anti-depressive properties to be
“obvious, opening interesting prospects, in particular in the
treatment of pharmaco-resistant major depressive patients”
(36). However, the effectiveness of rTMS has not only
demonstrated in treatment refractory patients. rTMS has also
been investigated in less treatment-resistant patients who might
beneﬁt even more from TMS than patients with pharmaco-
resistant depression (37).
Due to its good tolerability and because it is free of the side
effects that commonly accompany antidepressant medications, it
would also seem attractive to patients, who are not willing to take
a medication (38).January 2020 | Volume 10 | Article 929
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local pain, discomfort, headache, vasovagal syncope are reported,
and the induction of an epileptic seizure is the most important
safety concern of rTMS treatment (39). However, the incidence
of seizures with TMS is relatively low and is less evident than that
with current antidepressant medications (40).
In comparison to ECT, although the latter seem to have
higher response rates in treatment-resistant depression (41),
rTMS does not require anesthesia or muscle relaxation (does
not require induction of a seizure). Moreover, the magnetic
stimulation is delivered in a focal manner at a chosen cortical
target rather than affecting the entire brain as with ECT (42),
which signiﬁcantly reduces side effects (43). Furthermore, there
is no evidence of cognitive impairment connected to TMS, also
most adverse events of TMS are mild to moderate in intensity,
which leads to a low discontinuation rate due to adverse events
during the treatment course (40).
These summarized data with respect to efﬁcacy and side
effects propose rTMS as promising alternative or additional
intervention in the treatment of depression. Some researchers
have already reported a decrease of suicidal ideations following
treatment with rTMS (33, 44–46). These results however were
considered as preliminary because most of them were not sham-
controlled with mostly very limited suicide assessment measures
and relatively small sample sizes (47). In their study of open-label
accelerated TMS (aTMS) over 2 days in 14 depressed patients,
Holtzheimer et al. reported that only one patient showed
increased suicidal ideation (48).
In a Chinese randomized controlled trial, it has been found
that rTMS combined with medications reduces suicidal ideation
in elderly patients with depression (49). In their study of
applying high frequency TMS to the left dorsolateral prefrontal
cortex (DLPFC) on 19 adolescents with treatment-resistant
depression, Croarkin et al. reported improvement in suicidal
ideation across 30 sessions associated with improvement in
depressive symptom severity (50).
Our goal from this study was to investigate the relationship
between rTMS and suicidal risk in a more naturalistic sample,
which avoids the disadvantage that patients with high risk for
suicidality were typically excluded from rTMS treatment studies.
We conducted a retrospective analysis of a large dataset from
patients that received rTMS for the treatment of depression in a
real-world clinical setting of a tertiary referral hospital.METHODS
The analyses and publication of this retrospective work was
approved by the ethic committee of the University of Regensburg
(ethic vote: 16-104-0223). We revised and analyzed the records
of 711 patients with mood disorders, who were treated with
rTMS in the Center for Neuromodulation Regensburg
(Germany) between 2002 and 2017 excluding patients
receiving sham. One twenty-eight out of them were treated
more than one time with rTMS. The patients are referred to us
either from our different inpatients’ wards or from our outpatientFrontiers in Psychiatry | www.frontiersin.org 3clinic via the responsible psychiatrist. Those are typically the
patients who failed to show an adequate response to standard
therapies. Suicidality is not an exclusion criterion per se except
for acute suicidality which would be associated with
hospitalization in a closed station.
For this sample of 711 patients we report the number of
committed suicides within the course of the treatment
with rTMS.
In addition, we analyzed a subsample with respect to the effect
of rTMS on suicidal ideation based on the Hamilton depression
rating scale (HAMD). The inclusion criteria for the retrospective
analysis were: rTMS-naïve (only the patient’s ﬁrst treatment with
rTMS was considered), primary diagnosis of a depressive
disorder [including bipolar disorder currently depressive
episode (ICD-10: F31), major depressive disorder (ICD-10:
F32), and recurrent depressive disorder (ICD-10: F33)], a
complete documented HAMD at beginning and at the end of
rTMS treatment, absence of a serious somatic illness. Both in-
and outpatients were included.
We were able to collect data of 332 patients, who met the
above-mentioned criteria including 180 (54.2%) females and 152
(45.8%) males with an age range between 20 and 79 years (47.3 ±
12.3). Patients were treated with a minimum of 6 up to 50
sessions (17.0 ± 6.5). Patients received different rTMS protocols,
most of them received 20 Hz stimulation on the left prefrontal
cortex (Table 1).
The analysis was based on the scores of the 21-item Hamilton
Depression Rating scale (HDRS or HAMD) (51), which is
considered to be a reliable depression scale regarding internal
consistency, inter-rater and test-retest reliability (52). We
focused on the changes in the item 3 (suicidality). This item
evaluates the presence and severity of suicidal thoughts/action on
a 4-point scale, leveling from absence of suicidal thoughts (score
0) as the lowest score, the feeling that life is not worth living
(score 1), presence of death wishes (score 2), suicide ideas (score
3), till suicidal attempts (score 4), as the highest score.
We compared the baseline scores (at beginning of treatment)
with those at end of treatment, trying to ﬁnd out if the scores
would increase or decrease after the rTMS treatment. This was
done for all single items and also the sum score of the HAMD toTABLE 1 | Frequency of repetitive transcranial magnetic stimulation protocols
performed.
Protocol (frequency—site—daily
pulses)
Absolute number
of patients
Relative number
of patients
20 Hz—left prefrontal—2,000 261 78.6%
10 Hz—left prefrontal—2,000 15 4.5%
10 Hz—left prefrontal—1,000 10 3.0%
20 Hz—right prefrontal—2,000 3 0.9%
1 Hz—right prefrontal—1,000 1 0.3%
10 Hz—anterior cingulate cortex—
2,000
12 3.6%
20 Hz—left prefrontal followed by 1 Hz
—right prefrontal—2,000
11 3.3%
iTBS—left prefrontal followed by cTBS
—right prefrontal—2,400
19 5.7%January 2020 | Volume 10 | Article 929
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direction as change of other depressive symptoms. For item 3
we also looked in the change of the frequency of the single grades
of the question.
We’ve also tried to correlate the results with the scores of item
7 (work and abilities), which focuses mainly on the patient’s
energy and drive. The motivation for this analysis was twofold.
Firstly, it is assumed that energizing a depressed patient through
medication can also increase the risk of suicidality. Secondly, we
aimed to investigate whether improvement/worsening the
suicidal ideation is attributable to parallel improvement/
worsening of patient’s energy level. To see if a putative
association is speciﬁc we did this correlation for all items and
also for the sum score.
All data were analyzed using Statistical Package for the Social
Sciences (SPSS; IBM SPSS Statistics for Windows, Version
24.0.0.1). The signiﬁcance level was set at p < 0.05 for all
analyses. Signiﬁcant ﬁndings which survived correction for
multiple comparisons according to Bonferroni were separately
marked. For pre-post contrasts we used Wilcoxon rank sum
tests. For cross-tab analysis we used the chi-squared test of
independence. For correlations we used Spearman correlation
coefﬁcients. Effect sizes were reported by Cohen’s d (53), and
were calculated according to Lenhard & Lenhard (54).RESULTS
From the above-mentioned 711 patients, only one patient (0.1%)
committed suicide during the TMS treatment. In this single caseFrontiers in Psychiatry | www.frontiersin.org 4the role of TMS remains unclear. Nine years prior to his suicide,
this patient had already received a successful 15-days rTMS
treatment course. Re-hospitalization occurred because of another
depressive episode. After a short period, the patient was
discharged from the hospital. Due to re-emerging of suicidal
impulses immediately after hospital discharge the patient was
hospitalized again. After a month of hospitalization, because of
failed response to antidepressants, and also the prior treatment
success of TMS, a new treatment course was proposed. After the
ﬁrst TMS session, he was seen by a doctor. He appeared to be
calm, claimed to be in a good mood and denied having any
suicidal thoughts. Also, in his conversations with nursing staff
and a phone call with a relative afterwards, the patient appeared
to be in a stable condition free from suicidal ideation. Later on
that day, he left the clinic ward, didn’t answer his cell phone
anymore and sadly then committed suicide. Finally, the reasons
for the suicide remained unclear. To which extent the underlying
depressive disorder, the used therapies (medication,
psychotherapy, rTMS), or any other factors contributed to the
suicide, couldn’t be identiﬁed.
In the statistical analysis of the subsample with 332 patients
there was an overall amelioration of depressive symptoms
accompanied by a signiﬁcant decrease in the suicidality item
with a large effect size. Only three items did not survive
correction for multiple comparisons. Decrease in suicidality
was not inferior to changes in other items as indicated by effect
sizes (Figure 1). The chi-square test of independence was
signiﬁcant (c² = 43.318; df = 12; p < 0.001) showing an
association of the severity of depression before and
after rTMS.FIGURE 1 | Difference between baseline and ﬁnal scores of the Hamilton Depression Rating Scale items. *indicate signiﬁcant Wilcoxon tests which survived
correction for multiple comparisons. Z corresponds to the z-value of the test statistic and d to the effect size. Please note that for reasons of similar scale the overall
score is shown not as sum but as average score.January 2020 | Volume 10 | Article 929
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the baseline rating, to 208 patients at the ﬁnal rating. Also, less
patients scored 1, 2, and 3 at the ﬁnal rating (81, 33, 14
respectively) compared to the baseline rating (111, 72, 34
respectively). No patient scored 4 at the ﬁnal rating compared
to three patients at the baseline rating.
One hundred ﬁfty-six (47.0%) patients showed an
amelioration in suicidality. One patient showed amelioration
of 4 points (0.3%), 15 of 3 points (4.5%), 39 of 2 points (11.8%),
and 101 of 1 point (30.4%). One hundred thirty-seven (41.3%)
patients did not show a change in their suicidality’s scores.
Thirty-nine out of the 332 (11.7%) patients showed an increase
in suicidality from baseline to ﬁnal rating as indicated by
increase from 0 during baseline to 1, 2, or 3 during the ﬁnal
rating or from 1 during baseline to 2 or 3 during ﬁnal rating or
from 2 during baseline to 3 during ﬁnal rating. Twenty-nine
patients showed worsening of the scoring of 1 point (8.7%), 8
of 2 points (2.4%), and 2 of 3 points (0.6%). No patient
increased to the maximum score of 4. For absolute numbers
see (Figure 2).
Non-parametric Spearman correlation of item 3 (suicidality)
and 7 (drive) demonstrate a signiﬁcant positive association (r =
0.196; p < 0.001), that means that patients showed improvement
of their suicidality alongside with increased drive. Items 1 (r =
0.263; p < 0.001) and 2 (r = 0.265; p < 0.001) and sum score (r =
0.426; p < 0.001) also correlated signiﬁcantly on a Bonferroni
corrected level, the other items not.Frontiers in Psychiatry | www.frontiersin.org 5DISCUSSION
Suicidal ideation is a severe symptom of depressive disorders and
a huge concern for mental health providers. Only few treatments
for suicidal ideation and behavior (e.g., lithium, ECT) are
available and these are only partially effective. There is an
enormous need for more convenient interventions.
Therefore there is a great need to ﬁrstly develop new
treatment modalities with a rapid effect on suicide risk in order
to prevent suicide (18, 47) and to secondly assess the effects of
established antidepressant treatments on suicidal ideation.
Transcranial magnetic stimulation represents a non-invasive,
feasible, effective, and safe treatment option for depression (55).
There are no published reports that TMS increases suicide risk
(56). However, there is only relatively few systematic research
about the effect of rTMS on suicidality. In our analysis, which
comprised a large sample of 711 patients, we found an overall
improvement of suicidal ideation represented in item 3 of the
HAMD score. The improvement in this item corresponded well
to the overall improvement in the total HAMD score; 88.3% of all
patients showed either improvement or stability of their suicidal
ideation score, compared to 11.7% in which the score worsened
under the TMS treatment course. Together with the signiﬁcant
chi-square test, we can conclude that we found no evidence that
rTMS systematically increases suicidality.
Also, we found a positive correlation between improved
patient’s drive (indicated by item-7 score) and improvedFIGURE 2 | Absolute frequencies of the single values of the suicidality item 3 of the Hamilton Depression Rating Scale.January 2020 | Volume 10 | Article 929
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were also signiﬁcantly associated with change in the total score
and with change in the items 1 and 2 (depressed mood and
feeling of guilt). The changes of all other items showed smaller
and non-signiﬁcant correlations. We interpret this in a way that
change in suicidality is associated with changes in the main
symptoms of depression considering that suicidality is also one
main symptom of depression. Thus, we found no hint that rTMS
induces an energizing effect without improvement of mood and
that such a constellation may increase suicidality.
Our results get in line with some prior research revealing
alleviation of suicidal ideation under TMS treatment. Hadley et
al. reported in their trial on the effect of rTMS in patients with
treatment-resistant unipolar or bipolar depression improvement
of all measured dimensions, and most importantly, that suicidal
ideation diminished in 67% of the patients already after the ﬁrst
week of treatment (57). In another 3 days-trial of delivering high
doses of rTMS on left prefrontal cortex in patients with suicidal
ideations, a more rapid decline in suicidal thinking has been
observed in the active rTMS group compared to the sham group.
The rather intense stimulation schedule (delivering 54,000
stimuli over 3 days), was feasible and safe with minimum side
effects, and particularly with no worsening of suicidal thinking
(58). Desmyter et al. examined in a randomized, sham-controlled
trial, the effects and safety of accelerated intermittent Theta Burst
Stimulation (iTBS) on suicide risk by using the Beck scale of
suicide (BSI). A signiﬁcant decrease of the BSI score over time
was observed for both active and sham stimulation and unrelated
to depression-response. There was no worsening of suicidal
ideation, and the decrease in suicide risk lasted up to 1 month
after baseline, even in depression non-responders (46).
Weissmann et al. compared the effect of bilateral, left unilateral
DLPFC, and sham rTMS on suicidal ideation in patients with
TRD (who failed to respond to at least two antidepressant
medications). They found a signiﬁcant superiority of bilateral
rTMS to sham rTMS in reducing suicidal ideation, with only a
small portion of this reduction in suicidal ideation attributable to
the improvement of overall depressive symptoms (59).
In our sample, among 711 patients that were treated with
rTMS there was only one single suicide. For this suicide no
obvious causal relation with rTMS treatment could be
established. In most of the 711 patients, rTMS was not
performed in the context of a clinical trial (where a high
suicide risk is frequently an exclusion criterion), but as
compassionate use treatment because of treatment resistance to
medication and psychotherapy. This means that the sample
consisted of treatment resistant patients with a rather high
suicide risk. Our ﬁndings not only give a powerful indicator
for the safety of TMS regarding suicidality, but also present TMS
as a potential therapy option to reduce suicidal ideation.
This notion is supported by the presumed mechanism of
action of prefrontal TMS namely the improvement of cortical-
limbic regulatory control over emotional drive (60). The suicidal
crisis has been described as a dysfunctional brain event, related to
changes in the prefrontal cortex which leads to deﬁcientFrontiers in Psychiatry | www.frontiersin.org 6regulation of the emotional state (61). Baeken et al. investigated
how accelerated iTBS (aiTBS) may inﬂuence brain perfusion and
suicidal thoughts using arterial spin labeling (ASL) fMRI, they
found that both active and sham aiTBS resulted in prompt
decreases in suicidal ideation, but speciﬁcally sham aiTBS has
signiﬁcantly attenuated frontopolar perfusion in relation to
reductions in BSI scores. They interpreted those ﬁndings that in
accelerated neurostimulation paradigms, placebo responses are
related to perfusion decreases in brain areas associated with higher
cognitive processes such as the default mode network, resulting in
suicidal ideation attenuation (62).
Whereas our results demonstrate the effectivity of rTMS on
suicidal ideation, we are aware of several limitations of the study.
Firstly, this is a retrospective analysis, secondly rTMS was
applied as an add-on treatment. Thirdly there was no sham
control and fourthly there were no follow-up measures.
Additionally, the study depended on a single item of the
HAMD scale and not a speciﬁc assessment scale for suicidality
e.g., the Beck Scale for Suicidal Ideation (63). Also, only three
subjects of the sample had endorsed suicidal behavior (scoring 4
at the item 3 at baseline rating), that means that the analysis was
more based on examining suicidal ideation, not suicidal
behavior. Despite these limitations, the analysis of this
relatively large sample indicates, that there is no hint for an
induction of suicidal behavior by rTMS treatment. In contrary
our data suggest that during rTMS treatment suicidal risk
decreases together with an improvement of other core
symptoms of depression.
We call through our work for further prospective studies of
rTMS in depression that focus more explicitly on the effect of
rTMS on suicidal ideation and suicide risk. Moreover, our data
suggest that further studies are warranted that directly
investigate the effects of rTMS on suicidal ideation not only in
patients with depression, but also in other psychiatric disorders.CONCLUSION
Based on the proposed data, there is no evidence that rTMS
increases the risk for suicidality during the course of the
treatment. Conversely, rTMS tends to reduce suicidal ideation.
Our ﬁndings call for further rTMS controlled studies using large
sample sizes and speciﬁc suicidality assessment measures to
obtain more conclusive results.DATA AVAILABILITY STATEMENT
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